What is Exogenesis?
Headquartered in Billerica, Massachusetts, Exogenesis operates at the intersection of material science and advanced engineering. The company has pioneered the NanoAccel platform, which leverages Accelerated Neutral Atom Beam (ANAB) and Gas Cluster Ion Beam (GCIB) technologies to manipulate material surfaces at the nanoscale. By enabling precise surface control without the need for traditional coatings or the risk of sub-surface damage, Exogenesis provides critical solutions for the biomedical, optical, and semiconductor industries. This unique value proposition allows the company to address complex manufacturing challenges where surface integrity is paramount to product performance and reliability.
How much funding has Exogenesis raised?
Exogenesis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Exogenesis
PPP
Public-Private Partnership
What's next for Exogenesis?
With this late-stage capital, Exogenesis is poised to scale its operations and deepen its market penetration across its core verticals. The strategic focus will likely shift toward expanding the industrial application of the NanoAccel platform, moving from pilot-scale implementations to full-scale commercial integration. As the demand for high-performance materials continues to rise in the semiconductor and medical device sectors, Exogenesis is strategically positioned to become a foundational technology provider. Future growth will depend on the company's ability to maintain its technological edge while navigating the rigorous regulatory and quality standards inherent in its target markets.
See full Exogenesis company page
